J&J to pay $30 billion for Actelion | January 30, 2017 Issue - Vol. 95 Issue 5 | Chemical & Engineering News
Volume 95 Issue 5 | News of The Week
Issue Date: January 30, 2017 | Web Date: January 26, 2017

J&J to pay $30 billion for Actelion

A new biotech will be created from Actelion’s research unit
Department: Business
Keywords: mergers & acquisitions, Actelion, Delinia, pharmaceuticals, biotech
[+]Enlarge
Actelion’s research activities will be spun out into a new firm.
Credit: Actelion
A photo of Actelion researchers.
 
Actelion’s research activities will be spun out into a new firm.
Credit: Actelion

Ending months of negotiations, Johnson & Johnson will pay $30 billion to acquire the Swiss biotech firm Actelion. The proposed transaction is the biggest to date in a year expected to bring significant deal-making by big pharmaceutical companies.

The purchase—the biggest ever for J&J—gives the pharma firm a portfolio of treatments for pulmonary arterial hypertension (PAH), a rare type of high blood pressure that affects the lungs and heart. Those PAH drugs collectively brought in more than $2 billion in sales in 2015.

Actelion first confirmed in November that J&J had approached with a takeover offer, though by December, Sanofi emerged as a possible suitor.

Ultimately, J&J, which is grappling with new competition in the U.S. for its top-selling drug, Remicade, was willing to get creative with the structure of the deal.

Although the big pharma firm is capturing Actelion’s PAH portfolio and late-stage pipeline, Actelion’s drug discovery activities and some early-stage drug candidates will be spun out into a newly created biotech firm. J&J will hold a 16% stake in the new company, and has the right to later buy another 16%.

[+]Enlarge
Clozel
Credit: Actelion
A photo of Actelion CEO Clozel.
 
Clozel
Credit: Actelion

The yet-to-be-named biotech will be outfitted with $930 million in cash and run by Actelion’s existing scientific team, retaining upwards of 700 out of Actelion’s 2,500 employees, Jean-Paul Clozel, founder and CEO of Actelion, said at a press conference. Clozel will lead the new company.

The purchase of Actelion is the first major deal in a year expected to bring heavy merger and acquisition activity as drug firms grapple with pressures ranging from lagging productivity, new competition from biosimilars, and uncertainty around drug pricing.

Celgene added to this year’s mergers & acquisitions tally, saying today it would pay $300 million up front to acquire Delinia, a privately held biotech firm developing treatments for autoimmune diseases. Delinia’s shareholders could see another $475 million in milestone payments as its molecules advance into the clinic.

Delinia was just launched in September, when it announced it had raised $35 million in funding from Atlas Venture and Sofinnova Partners to develop proteins that can modulate the activity of regulatory T cells.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Comments
BabyBoomerWriter (Sat Mar 11 10:38:42 EST 2017)
When large chemical/pharmaceutical giants gobble up smaller entities they run the risk of losing the start up culture that fueled innovation. Why not allow a successful young firm, whose culture is often anithetical to that of the mega-giant buyer, continue as a separate affiliated entity, with their own leadership?

Public companies with notable boards and lots of press coverage are not allowed the missteps a younger company needs to keep its employees energized. Young scientists are attracted to a flexible culture not typically found in giant labs with a top-down approach. Retaining young scientists who might not have chosen industry over academia but for the comfortable environment, is the best way to foster innovation.

Leave A Comment

*Required to comment